Relief Therapeutics Holding SA (QB) (RLFTY) 銘柄情報

Up three days in a row in a down market

Up three days in a row in a down market

What's all this then?

Management, it seems, can not start a fire with a box of matches.
Making some deals with a big pharma company would seem to be a good path..
This is pretty sad, gone from high hopes during first two years of covid,
and covid is still going around today, with no news about relief on the international stage or
in the US, by the management, (from what I have noticed at least).
When the stock gets back to 2 cents....I guess it'll be a buy again. looks ugly right now.

Any miracles on the horizon for Relief T? guess we're just waiting for chapter 11!....SMH

Is this fancy language for another R/S ???
Capital Reduction by Reduction of Nominal Value
The Board proposes to reduce the nominal value of the Company's share capital from CHF 56'163'348.00 to CHF 1'404'083.70 by reducing the nominal value of each share from CHF 4.00 to CHF 0.10. This technical adjustment comes as the share currently quotes at a price below its par value. This situation presents practical implications, including limiting the Company's ability to raise capital. The number of outstanding shares, as well as shareholders' financial and patrimonial rights, will not be affected by the reduction in par value. The modification of the share capital shall render the capital band provisions under the Articles of Association void.

Looks like JJ scammed all the investors....whatever happen to Dr. Joey Johnson ...haven't seen him post in 2 years...he was good for some optimism in Relief T. at the very least...

Unfortunately the failed trial with NIH has spoiled aviptadil IMO. And without the FDA backing this is going nowhere. Hope they prove me wrong.

All the talk about NASDAQ was b.s. I'm sure they have been diluting the crap out of this to pay their high salaries and bonuses. Which means another r/s may be in the making in 2025 (or earlier).

The simple truth is, this company does not have a product that can generate reasonable revenues. It's always been one big pipe dream. FDA approval via COVID was the one big crap shoot with high profit potential. It's gone now.

When will the breakthrough come? https://medriva.com/health/respiratory-health/revolutionizing-respiratory-treatment-unveiling-the-potential-of-new-cell-therapy/

Hey Joe.......The annual incidence of ARDS is around 60 cases per 100,000 people. Approximately 2% of all patients admitted to intensive care units meet the criteria for ARDS.18.08.2023................and now we know that AVIPTADIL has already been approved in the EU ! https://www.vfa.de/de/arzneimittel-forschung/woran-wir-forschen/therapeutische-medikamente-gegen-die-coronavirusinfektion-covid-19 Here is a text from the current report of the research-based pharmaceutical industry, originally written in German ................

4. Medicines for lung function
The vital task of the lungs is to ensure the exchange of gases between the air we breathe and the blood. Seriously ill corona patients are in danger of losing their lives if this no longer works sufficiently. What is then essential for recovery is that the lungs can regenerate with functional tissue and not just scar tissue.

One of the drugs being tested for maintaining lung function contains the active ingredient Aviptadil, a synthetic version of the naturally occurring molecule VIP in humans. The Swiss company Relief Therapeutics has approval in the EU for the treatment of acute respiratory distress syndrome (ARDS) and sarcoidosis, but has not yet brought it onto the market in Germany. The active ingredient works, among other things: anti-inflammatory and protects certain lung cells (alveolar type 2 cells) from viral attack. They are a preferred target of SARS-CoV-2 and are particularly important for maintaining lung function. Following positive laboratory data, the company NeuroRx conducted a phase II/III study with seriously ill Covid-19 patients (symptoms of severe lung failure; ventilated) in the USA with the support of Relief Therapeutics. With intravenous therapy, patients recovered more quickly from respiratory symptoms. NeuRx then applied for an Emergency Use Authorization from the FDA. A long-term study (1 year follow-up) with patients with serious previous illnesses suggested that VIP improved their survival by 60%. However, in another study with seriously ill Covid-19 patients, Aviptadil did not show any effectiveness. Relief Therapeutics has also started a phase II study with an inhalable formulation of the active ingredient together with the company AdVita Lifescience in Saarbrücken. The aim here is also to avoid acute respiratory distress syndrome in Covid-19 patients.

rollup....great work rollup...greatly appreciated, all excellent news, and a reason to remain very hopeful. 😀

selected quotes from your link.........w the Indian Journal of Critical Care Medicine
"Effect of Aviptadil, a Novel Therapy, on Clinical Outcomes of Patients with Viral-related Severe ARDS:"
"Background: Dealing with life-threatening viral acute respiratory distress syndrome (ARDS) has always been challenging and with the recent COVID pandemic experience, there is still the need of newer therapies to alleviate mortality. Aviptadil, has shown significant beneficial results in COVID. We share our experience with this molecule by doing a retrospective study to evaluate the effect of this drug on clinical outcomes in viral-related ARDS patients."
"Conclusion: Aviptadil has shown to improve the clinical outcomes in patients with severe viral-related ARDS without any adverse effects"

Any old figures for the global dollar value of ARDS medications out there.. ???

Joe Kaplan, here is the brand new answer to your request! Indian Journal of Critical Care Medicine, Volume 28 Issue 1 (January 2024)
https://www.ijccm.org/abstractArticleContentBrowse/IJCCM/64/28/1/34862/abstractArticle/Article ------ read in the article PDF.....Considering these properties of VIP, aviptadil was launched, and this molecule received the US Food and Drug Administration (FDA) Fast Track Designation in June 2020 for dealing critical COVID-19 with respiratory failure. Aviptadil, a synthetic form of VIP, also named as RLF-100, is at present under phase II/III clinical trials. This drug has been designated as an orphan drug by FDA and has been used in past to treat respiratory airway diseases, such as asthma, chronic obstructive pulmonary disease (COPD), ARDS, and sarcoidosis.17 The first reported use of intravenous aviptadil was by Youssef et al., who used this drug to treat double-lung transplant COVID patient with respiratory failure. A dramatic recovery was seen and the patient was discharged in satisfactory condition.

ZUVENTUS = OXYPTADIL = AVIPTADIL = RLF100 = Relief Therapeutic😀

Pegs, ...very sympathetic about your interstitial lung issues. Hopes and prayers for big improvements in the new year. The progress with aviptadil is disappointing for me at this time. ... I have hoped there will be some much better progress with big pharma in india or japan or especially a swiss company. Still hoping for a better 2024....
Interesting company in solid state battery tech is ENVX fyi

Pegs,

IMO I think working through India is your best bet. I think we are years away in the USA before aviptadil is FDA approved for anything.

What is the ticker symbol for that EV battery stock? I'll put it on my watch list.

Take care, and I wish you the best. Keep fighting the fight!

Penny
It's been a long time since posting to you. I'm still alive with My interstitial lung disease. Can you tell me if aviptadil is dead or alive? Last I heard was that India was treating covid patients with it successfully. That trials were going on in Europe. My pulmonologist are saying that all medications have been exhausted for my condition. So I'm back to stem cell therapy. But it's so expensive! I was hoping that aviptadil would make a come back. But reading a couple of posts tell me that dilution & RSare on your horizon. I hate to see that happen to you guys. I've been through 3 RS which were brutal! I now only have 1 penny stock. It's on the verge of being the only highest energy dense battery worldwide for Electric Vehicls. Ford has lined up to test the battery out. So I'm hopeful for 2024 to be prosperous. I need the money to fund my stem cells until newer drugs are on the market. Wishing you all Happy Holidays.......Pegs

Relief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing Milestone

https://finance.yahoo.com/news/relief-therapeutics-announces-more-400-052000953.html

GENEVA, SWITZERLAND / ACCESSWIRE / October 10, 2023 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, today announced that over 400,000 of its ADRs are now outstanding. Since one of the key requirements for a NASDAQ listing of ADRs is the requirement that a company have more than 400,000 ADRs outstanding at the time of its initial listing, this important milestone has now been achieved. If Relief is successful in listing its ADRs on the NASDAQ Stock Market, Relief's ADR listing will complement the existing listing of its ordinary shares on the SIX Swiss Exchange.
Relief Therapeutics Holdings AG, Friday, May 26, 2023, Press release picture
Relief Therapeutics Holdings AG, Friday, May 26, 2023, Press release picture

"We are pleased that our shareholders have contributed ordinary shares in return for ADRs in an effort to aid in our objective of listing our ADRs on a U.S. national securities exchange," said Jack Weinstein, chief executive officer of Relief. "Once the remaining requirements for listing are met, which primarily includes achieving a market price of $4.00 per ADR, we intend to progress quickly towards a NASDAQ listing of our ADRs." Mr. Weinstein continued, "Achieving a listing of our ADRs on a U.S. national exchange will broaden the pool of institutional investors able to invest both with open market purchases of our ADRs and in potential future U.S. offerings. We believe that Relief can obtain a NASDAQ listing status by the end of this year, and we are currently exploring several avenues to meet the remaining NASDAQ initial listing requirements."

2023 Half Year Report..........
https://relieftherapeutics.com/images/pdf/RELIEF_Half-Year_Report_2023Final_with_hyperlinks4.pdf

At least this PR will result in RLFTF receiving REVENUES from the ACER partnership. It's prorgess.

https://relieftherapeutics.com/newsblog-detail/?newsID=2585961

https://quotes.freerealtime.com/quotes/RLFTF/Time%26Sales

safe and effective.......mgmt needs to to broadcast the message... looks like a
new round of covid being mfg.

Up, up on nice volume today.
Is good news on the way ?

ACER earnings out. Not was I was hoping for. Looks like they are out of money now.
https://finance.yahoo.com/news/acer-therapeutics-reports-second-quarter-200500038.html

Up over 8 percent today on no news and low volume.

Any one with any info ??

Frustrating.

Usually they put our communication announcements once a week. Been totally quiet for three weeks.

Good morning! I wish I had some insight but, no, I know nothing and i haven’t come across any news.

Does anyone have any idea what is going on with this company? Nasdaq is a laughable objective in my opinion and the loss of stockholders value is deplorable.

Same here!

Wish they would halt trading until they get their act together. Lost more money on this investment than ever before

Thanks Penny.

I don't believe RLFFD is the correct symbol anymore. Should be RLFTF. I'll PM IHUB

Are we halted or simply not trading?

I'm surprised that GEM went along with the R/S strategy. No NASDAQ uplisting in sight. Most reverse splits use that lame excuse to keep the SH at aby, and then never deliver. We'll see what happens here.

Unfortunately, once they do one R/S....it's very easy to do another, and another. So if the pps drifts down to a buck (from dilution) I predict another R/S.

Some very powerful good news is needed to resurrect this dog. ACER has a $1M cash infusion now, so maybe they will get the show on the road with generating revenues soon.

Stock went down another 15% today. Thieves for sure. 30,000 shares and now 75 and have lost 75% of the value. Class action suit is in order. Take the management income off the table.

Acer Therapeutics Receives $1 Million Capital Infusion from Chief Executive Officer and Founder

This should be good for RLFTF.
https://finance.yahoo.com/news/acer-therapeutics-receives-1-million-123000673.html

4 Hot Penny Stocks Making Waves : ALKM, FBCD, RMHI, RLFTF June 23, 2023
https://www.drpjournal.com/4-hot-penny-stocks-making-waves-alkm-stgz-fbcd-rmhi/

Agree 100%

It's about time!!! Their compensation packages should be frozen until they can start to generate sales of some sort. Their priorities are all backwards. RAM should be fired and replaced with someone who understands how to balance sales and marketing with R&D.

The annual meeting showcases the discontent of shareholders with the management and BOD.

not a clue. they stopped communicating matters of interest to the SH. I’ve always felt that the nasdaq talk was gibberish that penny stock ceo’s always say to appease SH before a devastating R/S. And they never shared with the SH their final analysis of the trial data that NRX was forced to give them. off the radar.

So far a terrible investment. What are they doing about uplisting to Nasdaq

More dilution....The management salaries and bonus checks must be paid on the backs of the SH. Someday the fat cats will start doing their job and find a way to generate sales.

"..... Relief Therapeutics plans to use the net proceeds from the private placement for working capital and other general corporate purposes."

https://finance.yahoo.com/news/relief-therapeutics-holding-sa-announces-053000386.html

In theory, this should help RLFFD. --- Acer Therapeutics Inc gets a Sentiment Score of Bullish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target of $9.67 https://www.investorsobserver.com/news/stock-update/healthcare-stocks-moving-wednesday-pbla-chek-acer-indp-namsw-nams-carm-zlab

Why are they not letting stockholders know what’s going on other than the persistent drop in value. Management is a catastrophe

Dr presenting on Avip and ARDS

I know, $3000 is ridiculous

Unfortunately the IRS only permits 3K write-off per year.

RVVTF has gotten hammered too. They thought they had a covid pill, but the FDA said... 'not so fast'. And there goes their PPS. It wasn't too long ago and they were sitting at 40 cents.

Well looks like a nice tax write off this year. What a terribly run company.

I read it the same way. I was hanging my hat on the EUA. The O/S is grossly toooooo high for a company that has never made a profit. I've always known the O/S was a major risk. So I can't blame the company. I knew what I was getting into. Even if they manage to get to the NASDAQ I don't see how that will help the investors without some great news. I don't believe that the profits from the ACE drug sales will be enough to make a dent. Manage gets their high salaries and stock options on the back of the common shareholders. I'm afraid that more dilution is inevitable and we'll see yet another R/S. Once they do one, the next one is easy. Just being honest here. It would take some major news either on the FDA front or on the revenue front to turn this around. There is always the chance for great news. But if that were the case, WHY are they preparing us for more dilution per the recent PR. I queried this on the www............

Is an increase in share capital good or bad?

An increase in the total capital stock showing on a company's balance sheet is usually bad news for stockholders because it represents the issuance of additional stock shares, which dilute the value of investors' existing shares.

Read today that they are going to ask for more shares to be added at their annual meeting. Did I read that correctly in their announcement?

This stock has been a disaster for long term holders. Lost a small fortune in value. What, if any, options do we have as stockholders of this company?